AstraZeneca (AZN) said Friday that the US Food and Drug Administration has approved its experimental drug, calquence, combined with bendamustine and rituximab, for the treatment of certain adult patients with previously untreated mantle cell lymphoma.
The company said the approval was based on phase III results that showed calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy.
The drugmaker also said the approval converts calquence's earlier accelerated approval, granted by the FDA in October 2017, into full approval for adult mantle cell lymphoma patients.
AZN shares were 0.3% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。